NCT05602961View on ClinicalTrials.gov

A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 21, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
COVID-19
Interventions
DRUG

GLB-COV2-043

COVID-19 vaccine, administered as a booster

DRUG

BNT162b2/COMIRNATY®

active control

Sponsors
All Listed Sponsors
lead

GreenLight Biosciences, Inc.

INDUSTRY